Angiotensin II AT 1 Receptor blockers ameliorate inflammatory stress: A beneficial effect for the treatment of brain disorders

Cellular and Molecular Neurobiology

Volumn 32, Issue 5, 2012, Pages 667-681

  Saavedra, Juan M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Alzheimer's disease; Angiotensin II AT 1 receptor blockers; Anxiety; Brain inflammation; Brain Renin Angiotensin system; Cognition; Depression; Mood disorders; Neurodegenerative disorders; Stress; Stroke

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN; SARTAN DERIVATIVE;

ALLOSTATIC LOAD; ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANXIETY; BRAIN BLOOD VESSEL; BRAIN DISEASE; BRAIN ISCHEMIA; BRAIN NERVE CELL; BRAIN TISSUE; CARDIOVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; ENDOTHELIUM CELL; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; HEREDITARY HYPERTENSION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; INNATE IMMUNITY; MENTAL STRESS; METABOLIC DISORDER; MICROGLIA; MONOCYTE; MOOD DISORDER; NERVOUS SYSTEM PARAMETERS; NEUROPROTECTION; NONHUMAN; PARENCHYMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BRAIN DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, INNATE; INFLAMMATION; STRESS, PHYSIOLOGICAL;

BACTERIA (MICROORGANISMS); RODENTIA;

EID: 84864704525     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-011-9754-6     Document Type: Review

References (100)

1. Allen AM, MacGregor DP, McKinley MJ, Mendelsohn FA (1999) Angiotensin II receptors in the human brain. Regul Pept 79:1-7 (Pubitemid 29012453)
2. Anderson C (2010) More indirect evidence of potential neuroprotective benefits of Angiotensin receptor blockers. J Hypertens 28:429
3. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM (2004) Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 35:1726-1731 (Pubitemid 38823655)
4. Anisman H (2009) Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 34:4-20
5. Armando I, Carranza A, Nishimura Y, Hoe KL, Barontini M, Terrón JA, Falcón-Neri A, Ito T, Juorio AV, Saavedra JM (2001) Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. Endocrinology 142:3880-3889 (Pubitemid 32802660)
6. Armando I, Volpi S, Aguilera G, Saavedra JM (2007) Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res 1142: 92-99 (Pubitemid 46420692)
7. Bader M (2010) Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Ann Rev Pharm Tox 50:439-465
8. Baiardi G, Bregonzio C, Jezova M, Armando I, Saavedra JM (2004) Angiotensin II AT1 receptor blockade prolongs the lifespan of spontaneously hypertensive rats and reduces stress-induced release of catecholamines, glucocorticoids, and vasopressin. Ann N Y Acad Sci 1018:131-136 (Pubitemid 38951399)
9. Barra S, Vitagliano A, Cuomo V, Vitagliano G, Gaeta G (2009) Vascular and metabolic effects of angiotensin II receptor blockers. Exp Opin Pharmacother 10:173-189
10. Benicky J, Sánchez-Lemus E, Pavel J, Saavedra JM (2009) Antiinflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol 29:781-792
11. Benicky J, Sánchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, Leng Y, Chuang DM, Saavedra JM (2011) Angiotensin II AT(1) receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 36:857-870
12. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G (2009) Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119:524-530
13. Braszko JJ, Karwowska-Polecka W, Halicka D, Gard PR (2003) Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J Basic Clin Physiol Pharmacol 14: 323-343 (Pubitemid 38679252)
14. Bravo JA, Dinan TG, Cryan JF (2011) Alterations in the central CRF system of two different rat models of comorbid depression and functional gastrointestinal disorders. Int J Neuropsychopharmacol 14:666-683
15. Bregonzio C, Armando I, Ando H, Jezova M, Baiardi G, Saavedra JM (2003) Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am J Physiol Gastrointest Liver Physiol 285:G414-G423 (Pubitemid 36875214)
16. Bregonzio C, Seltzer A, Armando I, Pavel J, Saavedra JM (2008) Angiotensin II AT(1) receptor blockade selectively enhances brain AT(2) receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. Stress 11:457-466 (erratum in Stress 12:95, 2009)
17. Castrén E, Saavedra JM (1988) Repeated stress increases the density of Angiotensin II binding sites in rat paraventricular nucleus and subfornical organ. Endocrinology 122:370-372 (Pubitemid 18027626)
18. Chrysant SG (2006) Clinical experience with the use of Angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases. Curr Clin Pharmacol 1:139-146
19. Conner KR, Payne VS, Forbes ME, Robbins ME, Riddle DR (2010) Effects of the AT1 receptor antagonist L-158, 809 on microglia and neurogenesis after fractionated whole-brain irradiation. Radiat Res 173:49-61
20. Dantzer R, Bluthé RM, Gheusi G, Cremona S, Layé S, Parnet P, Kelley KW (1998) Molecular basis of sickness behavior. Ann N Y Acad Sci 856:132-138 (Pubitemid 28517345)
21. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46-56 (Pubitemid 350295688)
22. de Gasparo M, Siragy HM (1999) The AT2 receptor: fact, fancy and fantasy. Regul Pept 81:11-24 (Pubitemid 29248796)
23. Devereux RB, Dahlöf B (2007) Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr Med Res Opin 23:443-457 (Pubitemid 46333392)
24. Domschke K, Zwanzger P (2008) GABAergic and endocannabinoid dysfunction in anxiety - future therapeutic targets? Curr Pharm Des 14:3508-3517
25. Editorial (2007) Ensuring drug safety: lessons from the thiazolidinediones. Lancet 370:1101
26. Edwards E, King JA, Fray JC (1999) Increased basal activity of the HPA axis and renin-angiotensin system in congenital learned helpless rats exposed to stress early in development. Int J Dev Neurosci 17:805-812 (Pubitemid 29488558)
27. Fogari R, Zoppi A (2004) Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 21:377-393 (Pubitemid 38608506)
28. Gard PR, Haigh SJ, Cambursano PT, Warrington CA (2001) Strain differences in the anxiolytic effects of losartan in the mouse. Pharmacol Biochem Behav 69:35-40 (Pubitemid 32566243)
29. Grammatopoulos TN, Jones SM, Ahmadi FA, Hoover BR, Snell LD, Skoch J, Jhaveri VV, Poczobutt AM, Weyhenmeyer JA, Zawada WM (2007) Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener 2:1
30. Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13:85-94 (Pubitemid 32222977)
31. Hallevi H, Hazan-Halevy I, Paran E (2007) Modification of neutrophils adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. Eur J Neurol 14: 1002-1007 (Pubitemid 47300773)
32. Hanisch UK (2002) Microglia as a source and target of cytokines. Glia 40:140-155
33. Hertzman M, Adler LW, Arling B, Kern M (2005) Lisinopril may augment antidepressant response. J Clin Psychopharmacol 25: 618-620 (Pubitemid 41669067)
34. Ito T, Yamakawa H, Bregonzio C, Terrón JA, Falcón-Neri A, Saavedra JM (2002) Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 33:2297-2303 (Pubitemid 35014646)
35. Johnson AK, Grippo AJ (2006) Sadness and broken hearts: neurohumoral mechanisms and co-morbidity of ischemic heart disease and psychological depression. J Physiol Pharmacol 57(Suppl 11):5-29 (Pubitemid 46569831)
36. Julius S, Nesbitt SD, Egan BM, Weber M, Michelson EL, Kaciroti N, Black HR, Grimm RH, Messerli FH, Oparil S, Schork A, Trial of Preventing Hypertension (TROPHY) Study Investigators (2006) Feasibility of treating prehypertension with an Angiotensin-receptor blocker. N Engl J Med 354:1-13
37. Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH, Park DK, Sinn DI, Kim JM, Kim M, Roh JK (2007) Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 322:1051-1058 (Pubitemid 47295814)
38. Kaiser FC, Palmer GC, Wallace AV, Carr RD, Fraser-Rae L, Hallam C (1992) Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze. Neuroreport 3:922-924
39. Kang YM, Ma Y, Zheng JP, Elks C, Sriramula S, Yang ZM, Francis J (2009) Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc Res 82:503-512
40. Keck M, Holsboer F (2001) Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 22:835-844 (Pubitemid 32397736)
41. Kurihara T, Ozawa Y, Shinoda K, Nagai N, Inoue M, Oike Y, Tsubota K, Ishida S, Okano H (2006) Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci 47:5545-5552 (Pubitemid 46723808)
42. Lanz T, Ding Z, Ho PP, Luo J, Agrawal AN, Srinagesh H, Axtell R, Zhang H, Platten M, Wyss-Coray T, Steinman L (2010) Angiotensin II sustains brain inflammation in mice via TGFb. J Clin Invest 120:2782-2794
43. Larrayoz IM, Pang T, Benicky J, Pavel J, Sánchez-Lemus E, Saavedra JM (2009) Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes. J Hypertens 27: 2365-2376
44. Lee JW, Naidong W, Johnson T, Dzerk A, Miyabayashi T, Motohashi M (1995) Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine. J Chromatogr B Biomed Appl 670:287-298
45. Leonard BE (2007) Inflammation, depression and dementia: are they connected? Neurochem Res 32:1749-1756 (Pubitemid 47428863)
46. Li Z, Bains JS, Ferguson AV (1993) Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res Bull 30:33-39 (Pubitemid 23027188)
47. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of Angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340:b5465
48. Linz W, Heitsch H, Schölkens BA, Wiemer G (2000) Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension 35:908-913 (Pubitemid 30303949)
49. Lou M, Blume A, Zhao Y, Gohlke P, Deuschl G, Herdegen T, Culman J (2004) Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab 24:536-547 (Pubitemid 38608286)
50. Lu GC, Cheng JW, Zhu KM, Ma XJ, Shen FM, Su DF (2009) A systematic review of Angiotensin receptor blockers in preventing stroke. Stroke 40:3876-3878
51. Marchesi VT (2011) Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 25:5-13
52. Marchesi C, Paradis P, Schiffrin EL (2008) Role of the reninangiotensin system in vascular inflammation. Trends Pharmacol Sci 29:367-374
53. Matsumoto S, Shimodozono M, Miyata R, Kawahira K (2010) The Angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke. Int J Neurosci 120:372-380
54. McFarlane SI (2009) Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials. Expert Rev CardiovascTher 7:1363-1371
55. Mertens B, Vanderheyden P, Michotte Y, Sarre S (2010) The role of the central renin-angiotensin system in Parkinson's disease. J Renin Angiotensin Aldosterone Syst 11:49-56
56. Miller G (2010) Is pharma running out of brainy ideas? Science 329:502-504
57. Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K, Ishida S (2007) Suppression of diabetes-induced retinal inflammation by blocking the Angiotensin II type 1 receptor or its downstream nuclear factor-kB pathway. Invest Ophthalmol Vis Sci 48:4342-4350 (Pubitemid 351261068)
58. Nasr SJ, Crayton JW, Agarwal B, Wendt B, Kora R (2011) Lower frequency of antidepressant use in patients on renin-angiotensin-aldosterone system modifying medications. Cell Mol Neurobiol 31:615-618
59. Nimmo AJ, Vink R (2009) Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat CNS Drug Discov 4:86-95
60. Nishimura Y, Ito T, Saavedra JM (2000a) Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31:2478-2486
61. Nishimura Y, Ito T, Hoe K, Saavedra JM (2000b) Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 871:29-38 (Pubitemid 30406864)
62. Ozacmak VH, Sayan H, Cetin A, Akyildiz-Igdem A (2007) AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion. Neurochem Res 32:1314-1321 (Pubitemid 46988191)
63. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Skoog I, Trenkwalder P, Zanchetti A (2004) Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 44:1175-1180 (Pubitemid 39208870)
64. Pascoe MC, Crewther SG, Carey LM, Crewther DP (2011) Inflammation and depression: why poststroke depression may be the norm and not the exception. Int J Stroke 6:128-135
65. Pavlatou MG, Mastorakos G, Lekakis I, Liatis S, Vamvakou G, Zoumakis E, Papassotiriou I, Rabavilas AD, Katsilambros N, Chrousos GP (2008) Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. Stress 11:62-72
66. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L (2009) Blocking Angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1-andTH17-mediated autoimmunity. Proc Natl Acad Sci USA 106:14948-14953
67. Polidori C, Ciccocioppo R, Nisato D, Cazaubon C, Massi M (1998) Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment. Eur J Pharmacol 352:15-21 (Pubitemid 28359402)
68. Porrello ER, Delbridge LM, Thomas WG (2009) The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci 14:958-972
69. Quan N, Banks WA (2007) Brain-immune communication pathways. Brain Behav Immun 21:727-735 (Pubitemid 47002217)
70. Rivest S (2010) Interactions between the immune and neuroendocrine systems. Prog Brain Res 181:43-53
71. Robbins ME, Payne V, Tommasi E, Diz DI, Hsu FC, Brown WR, Wheeler KT, Olson J, Zhao W (2009) The AT1 receptor antagonist, L-158, 809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment. Int. J Radiat Oncol Biol Phys 73:499-505
72. Rompe F, Unger T, Steckelings UM (2010) The angiotensin AT2 receptor in inflammation. Drug News Perspect 23:104-111
73. Saavedra JM (1992) Brain and pituitary Angiotensin. Endocrin Rev 13:329-380
74. Saavedra JM (2005) Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 25:485-512 (Pubitemid 41199709)
75. Saavedra JM, Benicky J (2007) Brain and peripheral angiotensin II play a major role in stress. Stress 10:185-193 (Pubitemid 46789475)
76. Saavedra JM, Armando I, Bregonzio C, Juorio A, Macova M, Pavel J, Sanchez-Lemus E (2006) A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stressinduced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology. 31:1123-1134 (Pubitemid 43971830)
77. Saavedra JM, Sánchez-Lemus E, Benicky J (2011) Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications. Psychoneuroendocrinology 36:1-18
78. Sanchez-Lemus E, Murakami Y, Larrayoz-Roldan IM, Moughamian AJ, Pavel J, Nishioku T, Saavedra JM (2008) Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland. Endocrinology 149:5177-5188
79. Sánchez-Lemus E, Benicky J, Pavel J, Larrayoz IM, Zhou J, Baliova M, Nishioku T, Saavedra JM (2009a) Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen. Am J Physiol Regul Integr Comp Physiol 296:R1376-R1384
80. Sánchez-Lemus E, Benicky J, Pavel J, Saavedra JM (2009b) In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPSinduced innate immune response and ACTH release in rat pituitary gland. Brain Behav Immun 23:945-957
81. Savoia C, Schiffrin EL (2007) Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 112:375-384 (Pubitemid 46587452)
82. Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA (2008) Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology 70: 1858-1866 (Pubitemid 351653953)
83. Schwartz EA, Zhang WY, Karnik SK, Borwege S, Anand VR, Laine PS, Su Y, Reaven PD (2010) Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol 30:802-808
84. Seltzer A, Bregonzio C, Armando I, Baiardi G, Saavedra JM (2004) Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res 1028:9-18 (Pubitemid 39424173)
85. Shekhar A, Johnson PL, Sajdyk TJ, Fitz SD, Keim SR, Kelley PE, Gehlert DR, DiMicco JA (2006) Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. J Neurosci 26:9205-9215 (Pubitemid 44359847)
86. Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E (2004) Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 311:989-995 (Pubitemid 39612703)
87. Skrbic R, Igic R (2009) Seven decades of angiotensin (1939-2009). Peptides 30:1945-1950
88. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T (2010) Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol 61:509-521
89. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510-518
90. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251 (Pubitemid 23191415)
91. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M (2009) Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 54:782-787
92. Tsutsumi K, Saavedra JM (1991) Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 261:R209-R216
93. Wang JM, Tan J, Leenen FH (2003) Central nervous system blockade by peripheral administration of AT1 receptor blockers. J Cardiovasc Pharmacol 41:593-599 (Pubitemid 36373797)
94. Weber MA (2005) Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes. Manag Care Interface 18:47-54 (Pubitemid 40740546)
95. Weinberg AJ, Zappe DH, Ashton M, Weinberg MS (2004) Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 24:340-345 (Pubitemid 39070118)
96. Xang G, Xi ZX, Wan Y, Wang H, Bi G (1993) Changes in circulating and tissue Angiotensin II during acute and chronic stress. Biol Signals 2:166-172 (Pubitemid 24062644)
97. Yamakawa H, Jezova M, Ando H, Saavedra JM (2003) Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition. J Cereb Blood Flow Metab 23:371-380 (Pubitemid 36307581)
98. Zanchetti A, Elmfeldt D (2006) Findings and implications of the Study on Cognition and Prognosis in the Elderly (SCOPE) - a review. Blood Press 15:71-79 (Pubitemid 43878912)
99. Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T (2010) Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 171:852-858
100. Zhou J, Ando H, Macova M, Dou J, Saavedra JM (2005) Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 25:878-886 (Pubitemid 40905615)